Roy A. Whitfield, Director at NEKTAR THERAPEUTICS (NKTR), bought 5,000 shares at $59.80 ($290K) on 2018-06-06, disclosed to the SEC on 2018-06-07.
Open-market purchase of $290k NKTR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $55.22 | 1,600 | $88K | 30.4% |
| 2 | $59.07 | 2,000 | $118K | 40.7% |
| 3 | $59.80 | 1,400 | $84K | 28.8% |
| Total | $58.04 avg | 5,000 | $290K | 100% |
| Filing → |
| ILMN | SELL | 2016-08-15 | $669K | — | Filing → |
| ILMN | SELL | 2016-06-15 | $534K | — | Filing → |
| ILMN | SELL | 2016-04-14 | $680K | — | Filing → |